“We are optimistic that the celiac study will be, will be positive as well.”
→ Read the source episode
Forte's phase 2b randomized celiac disease study meets its primary endpoint(s)
John predicts Coursera will run two studies (biomarker and outcomes-based) for their PCSK9/angiotensinogen siRNA program
Greg Savonovich predicts the biotech sector will continue to rally through the rest of 2026
John predicts France will win the third-place match and Argentina will beat France 3-2 in the World Cup final on Sunday
Yaron Werber predicts Gilead's Anido Cell (anti-BCMA CAR-T) will receive FDA approval in December 2026
Matt Klein's company will launch brepacitinib within the next two to two and a half months
Yaron Werber expects Forte will report phase 2b celiac and phase 1b alopecia areata data by end of 2026
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.